All In Biotech

Drug Trial Radar · NCT03706079

Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)

Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 951 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

951

Actual

Start

Jan 7, 2019

Primary completion

Oct 26, 2021

Study completion May 18, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Amgen
First posted
Oct 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years, up to 81 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. The study consists of a treatment phase, followed by a follow-up phase where subjects will not receive IP. The length of the follow up phase is determined by which study the subject had previously completed.

Conditions

  • Asthma

Interventions

  • TezepelumabBiological

    Tezepelumab subcutaneous injection

  • PlaceboOther

    Placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Exposure Adjusted Incidence Rates of AEs/SAEsTime frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
  2. Total Time at RiskTime frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.

Locations

180 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama

  • Research Site

    Gilbert, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Palm Desert, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Westminster, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Kissimmee, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Boise, Idaho

  • Research Site

    Zachary, Louisiana

  • Research Site

    White Marsh, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Northfield, New Jersey

  • Research Site

    Brooklyn, New York

  • Research Site

    The Bronx, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Edmond, Oklahoma

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Medford, Oregon

  • Research Site

    Philadelphia, Pennsylvania

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.